Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer
Pancreatic Neoplasms
DRUG: Surufatinib|DRUG: TAS-102
Progression-Free Survival (PFS), PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator, up to 24 months
disease control rate (DCR), DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator, up to 24 months|overall survival (OS), OS is the time from enrollment to death due to any cause., up to 24 months|objective response rate (ORR), Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1., up to 24 months|quality of life (QoL), Assessing the quality of life of cancer patients by QLQ-C30, up to 24 months|adverse events (AE), overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use., up to 24 months
surufatinib:250mg,QD,Q4W TAS-102:35mg/m2,D1-5,D8-12,Q4W